# Left Atrioventricular Coupling Index Predicts Poor Prognosis in Acute Myocardial Infarction: A Single-Center Cohort Study

**Authors:** Chuyun Chen, Haolei Huang, Jia Jia, Fangfang Fan, Jie Jiang, Ying Yang, Yan Zhang

PMC · DOI: 10.3390/jcdd13020090 · 2026-02-11

## TL;DR

This study shows that a new heart function measure called LACI can predict poor outcomes in heart attack patients.

## Contribution

The study introduces LACI as a novel and independent predictor of adverse outcomes in acute myocardial infarction patients.

## Key findings

- Higher LACI values were significantly associated with increased risks of major adverse cardiovascular events.
- The optimal LACI cutoff for risk stratification was found to be 0.257.
- LACI was independently linked to all-cause death, cardiovascular death, and stroke after adjusting for other factors.

## Abstract

(1) Background: The left atrioventricular coupling index (LACI) is a novel parameter for evaluating cardiac function. This study focused on its association with major adverse cardiovascular events (MACEs) in acute myocardial infarction (AMI) patients. (2) Methods: A retrospective cohort of AMI patients from Peking University First Hospital was enrolled. All underwent transthoracic echocardiography on admission for LACI measurement. The primary endpoint was MACE (a composite of nonfatal stroke, nonfatal myocardial infarction, and cardiovascular death). (3) Results: Among 843 AMI patients (62.07 ± 12.24 years, 77.94% male), the median LACI was 0.24 (IQR 0.18–0.33). During a median follow-up of 4.31 years, 151 patients (17.91%) developed MACE. The optimal LACI cutoff for risk stratification was 0.257. After multivariable adjustment, each standard deviation increase in LACI was associated with significantly elevated risks of MACE (HR 1.17, 95% CI 1.02–1.34), all-cause death (HR 1.19, 95% CI 1.05–1.35), cardiovascular death (HR 1.33, 95% CI 1.10–1.61), and stroke (HR 1.23, 95% CI 1.05–1.43). (4) Conclusions: LACI is an independent predictor of poor prognosis in AMI patients and may serve as a valuable tool for risk stratification in secondary prevention.

## Linked entities

- **Diseases:** acute myocardial infarction (MONDO:0004781), stroke (MONDO:0005098)

## Full-text entities

- **Genes:** NPPB (natriuretic peptide B) [NCBI Gene 4879] {aka BNP, Iso-ANP}, TFPI (tissue factor pathway inhibitor) [NCBI Gene 7035] {aka EPI, LACI, TFI, TFPI1}
- **Diseases:** cerebrovascular disease (MESH:D002561), AMI (MESH:D009203), Cardiovascular Death (MESH:D002318), atrial fibrillation (MESH:D001281), hypertension (MESH:D006973), Death (MESH:D003643), thrombosis (MESH:D013927), acute myocardial injury (MESH:D056486), cardiac remodeling and dysfunction (MESH:D020257), heart pump dysfunction (MESH:D006331), atrial dilation (MESH:C563984), heart failure (MESH:D006333), infarct (MESH:D007238), angina (MESH:D000787), NSTEMI (MESH:D000072658), chronic kidney disease (MESH:D051436), plaque rupture (MESH:D012421), diabetes (MESH:D003920), myocardial stunning (MESH:D017682), atrial remodeling (MESH:D064752), dyslipidemia (MESH:D050171), coronary heart disease (MESH:D003327), injury to (MESH:D014947), inflammation (MESH:D007249), vasospasm (MESH:D020301), cardiomyopathy (MESH:D009202), Stroke (MESH:D020521), impaired left ventricular diastolic (MESH:D018487), STEMI (MESH:D000072657)
- **Chemicals:** ticagrelor (MESH:D000077486), ACEI (-), clopidogrel (MESH:D000077144), creatinine (MESH:D003404), alcohol (MESH:D000438), lipid (MESH:D008055), triglyceride (MESH:D014280), cholesterol (MESH:D002784), aspirin (MESH:D001241)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942090/full.md

---
Source: https://tomesphere.com/paper/PMC12942090